APRIL WISEMAN: Open Payments
NPI 1205470747 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,524 in 63 payments from 16 companies in 2025. Trend: 2023 $1,324 · 2024 $1,682 · 2025 $1,524
Food & beverage: $1,329Education: $195
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 12 | $304 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 7 | $228 |
| ABBVIE INC. | 12 | $216 |
| Janssen Biotech, Inc. | 5 | $196 |
| Novartis Pharmaceuticals Corporation | 4 | $100 |
| LEO Pharma Inc. | 4 | $99 |
| Regeneron Healthcare Solutions, Inc. | 3 | $78 |
| Incyte Corporation | 3 | $72 |
| Amgen Inc. | 2 | $42 |
| PFIZER INC. | 2 | $35 |
Products named: DUPIXENT, SKYRIZI, TREMFYA, ILUMYA, ADBRY, OPZELURA, LIBTAYO, Rhapsido.
Industry payments across TX — which companies pay providers there.
